Preoperative Fasting C-Peptide Predicts Type 2 Diabetes Mellitus Remission in Low-BMI Chinese Patients After Roux-en-Y Gastric Bypass

Objective

This study investigated the role of preoperative fasting C-peptide (FCP) levels in predicting diabetic outcomes in low-BMI Chinese patients following Roux-en-Y gastric bypass (RYGB) by comparing the metabolic outcomes of patients with FCP >?1 ng/ml versus FCP ≤?1 ng/ml.

Methods

The study sample included 78 type 2 diabetes mellitus patients with an average BMI 2 at baseline. Patients’ parameters were analyzed before and after surgery, with a 2-year follow-up. A univariate logistic regression analysis and multivariate analysis of variance between the remission and improvement group were performed to determine factors that were associated with type 2 diabetes remission after RYGB. Linear correlation analyses between FCP and metabolic parameters were performed. Patients were divided into two groups: FCP >?1 ng/ml and FCP ≤?1 ng/ml, with measured parameters compared between the groups.

Results

Patients’ fasting plasma glucose, 2-h postprandial plasma glucose, FCP, and HbA1c improved significantly after surgery (p?p = 2.39). FCP showed a significant linear correlation with fasting insulin and BMI (p??1 ng/ml and FCP ≤?1 ng/ml groups (p?=?0.01). The parameters of patients with FCP >?1 ng/ml, including BMI, plasma glucose, HbA1c, and plasma insulin, decreased markedly after surgery (p?

Conclusion

FCP level is a significant predictor of diabetes outcomes after RYGB in low-BMI Chinese patients. An FCP level of 1 ng/ml may be a useful threshold for predicting surgical prognosis, with FCP >?1 ng/ml predicting better clinical outcomes following RYGB.